Abbott Licenses Epigenomics' Methylation Biomarker IP for Cancer IVD | GenomeWeb
NEW YORK (GenomeWeb News) - Abbott and Epigenomics have penned a non-exclusive license and collaboration agreement to develop a colorectal cancer diagnostic based on Epigenomics' intellectual property, Epigenomics said today.
 
Under the terms of the agreement, Abbott has licensed worldwide rights to Epigenomics’ DNA methylation biomarker Septin 9, which the companies plan to develop into an in vitro diagnostic blood test for early detection of colorectal cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.